Nephros Inc. NEPH
Medical/Dental Instruments · data as of November 13, 2026
Nephros Inc. (NEPH) is a healthcare company listed in the US with a market value of about $33M. In the twelve months to September 30, 2026 it had revenue of $22M and net income of $2M, a net margin of 8.9%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 16.9, 5-year revenue growth of 17% a year, a 5-year average ROIC of -15%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 78% below the current price.
About Nephros
Nephros is listed in the US and classified in medical/dental instruments. Revenue went from $2M in 2014 to $19M in 2025, growth of about 24.1% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 7% over three years (dilution for shareholders). It spends 7% of revenue on research and development.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22M | $19M | $14M | $14M | $10M | $10M | $9M | $10M | $6M | $4M | $2M |
| Net income | $2M | $1M | $74000 | -$2M | -$7M | -$4M | -$5M | -$3M | -$3M | -$809000 | -$3M |
| Free cash flow | — | — | -$547000 | $752000 | -$3M | -$1M | -$7M | -$2M | — | — | -$2M |
| EPS (diluted) | $0.18 | $0.11 | $0.01 | $-0.15 | $-0.73 | $-0.41 | $-0.52 | $-0.45 | $-0.50 | $-0.18 | $-0.54 |
| Net margin | 8.9% | 6.3% | 0.5% | -11.1% | -74.0% | -37.9% | -52.9% | -30.8% | -59.8% | -21.2% | -130.7% |
| ROIC | — | 10.1% | 0.1% | -15.6% | -51.3% | -20.2% | -23.8% | -42.1% | -52.1% | -48.6% | -150.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Nephros’s P/E ratio?
About 16.9, based on the last twelve months of diluted earnings per share.
Is Nephros stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 78% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Nephros pay a dividend?
Not currently.
Is Nephros a good stock to buy?
We do not give buy or sell advice. Nephros scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.